vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit
Company profile
Ticker
BRNS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Vaccitech Ltd, Vaccitech plc
SEC CIK
Corporate docs
Subsidiaries
Barinthus Biotherapeutics Pty Limited • Vaccitech Oncology Limited • Barinthus Biotherapeutics (UK) Limited • Barinthus Biotherapeutics North America, Inc. • Barinthus Biotherapeutics Italia S.R.L. • Barinthus Biotherapeutics Switzerland GmbH ...
BRNS stock data
Latest filings (excl ownership)
8-K
Other Events
12 Jun 24
8-K
Regulation FD Disclosure
6 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
15 May 24
8-K/A
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
14 May 24
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
13 May 24
8-K
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
18 Apr 24
ARS
2023 FY
Annual report to shareholders
22 Mar 24
DEFA14A
Additional proxy soliciting materials
22 Mar 24
DEF 14A
Definitive proxy
22 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 129.97 mm | 129.97 mm | 129.97 mm | 129.97 mm | 129.97 mm | 129.97 mm |
Cash burn (monthly) | 4.04 mm | 5.11 mm | 5.64 mm | 6.61 mm | 3.94 mm | 4.96 mm |
Cash used (since last report) | 10.85 mm | 13.73 mm | 15.14 mm | 17.76 mm | 10.58 mm | 13.33 mm |
Cash remaining | 119.12 mm | 116.24 mm | 114.83 mm | 112.21 mm | 119.39 mm | 116.64 mm |
Runway (months of cash) | 29.5 | 22.7 | 20.4 | 17.0 | 30.3 | 23.5 |
Institutional ownership, Q4 2023
17.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 0 |
Closed positions | 9 |
Increased positions | 2 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 25.25 bn |
Total shares | 6.69 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
M&G Investment Management | 5.20 mm | $20.79 bn |
SC CHINA HOLDING | 1.42 mm | $4.30 bn |
Renaissance Technologies | 29.70 k | $110.00 k |
Ipswich Investment Management | 23.08 k | $85.15 mm |
MS Morgan Stanley | 16.47 k | $60.76 mm |
UBS UBS Group AG - Registered Shares | 1.55 k | $5.71 mm |
New England Capital Financial Advisors | 104.00 | $384.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Jun 24 | Leon Hooftman | Share Option Ordinary Shares | Grant | Acquire A | No | No | 2 | 195,166 | 390.33 k | 195,166 |
10 May 24 | Robin Wright | Share Option Ordinary Shares | Grant | Acquire A | No | No | 2.34 | 19,516 | 45.67 k | 19,516 |
10 May 24 | Alex Hammacher | Share Option Ordinary Shares | Grant | Acquire A | No | No | 2.34 | 19,516 | 45.67 k | 19,516 |
10 May 24 | Phillips Anne M. | Share Option Ordinary Shares | Grant | Acquire A | No | No | 2.34 | 19,516 | 45.67 k | 19,516 |
News
Barclays Maintains Overweight on Barinthus Biotherapeutics, Lowers Price Target to $3
13 Jun 24
Barinthus Bio To Prioritize Development Of VTP-300 In CHB And VTP-1000 In Celiac Disease
12 Jun 24
HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $8 Price Target
7 Jun 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
5 Jun 24
Barinthus Bio To Present VTP-300 Clinical Updates At EASL Congress 2024
22 May 24
Press releases
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12 Jun 24
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
6 Jun 24
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
13 May 24
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
1 May 24
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
18 Apr 24